Recombinant Anti-DLL4 x Anti-VEGF Bispecific Antibody (F(ab')2-scFv2) is designed to be expressed as two chains combined via a hinge region. The scFv of the anti-DLL4 specificity is fused to the C terminus of the anti-VEGF Fab fragment, or vice versa. This format comprises four binding sites (two same scFv regions and two same Fab fragments), two for each antigen. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Solid tumors therapy.